Hack C C, Wetzl M, Schmidt D, Beckmann M W
Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland.
Frauenklinik, Universitätsklinikum Erlangen, Universitätsstr. 21-23, 91054, Erlangen, Deutschland.
Radiologie (Heidelb). 2025 Mar;65(3):154-161. doi: 10.1007/s00117-024-01394-x. Epub 2024 Dec 6.
In recent years, various magnetic resonance (MRI) and positron emission tomography (PET) parameters have been investigated in breast cancer. Parametric imaging focuses on the visualization and quantification of biological, physiological, and pathological processes at the cellular and molecular level. It therefore provides important insights into the key processes in carcinogenesis and tumor progression. This article aims to illustrate the importance for the management of breast cancer.
Based on the current literature, an overview of the current state of parametric breast imaging and its importance in therapy management is given. Moreover, future opportunities and challenges are highlighted.
Parametric imaging in breast cancer includes MRI, nuclear medicine procedures such as PET, the combination of different techniques (PET-CT, PET-MRI) and the use of specific radiotracers. Parametric MRI of the breast mainly uses T2 and diffusion-weighted imaging (DWI) as well as dynamic contrast-enhanced MRI (CM-MRI). Quantitative and qualitative imaging biomarkers provide insights into tumor biology and allow conclusions to be drawn about the molecular subtype or prognosis.
Recently, parametric imaging has become established in breast diagnostics. It is constantly evolving and will continue to gain in importance in the forthcoming years. It offers the opportunity to improve the diagnosis and treatment management of breast cancer.
近年来，人们对乳腺癌的各种磁共振成像（MRI）和正电子发射断层扫描（PET）参数进行了研究。参数成像专注于在细胞和分子水平上对生物、生理和病理过程进行可视化和量化。因此，它为癌症发生和肿瘤进展的关键过程提供了重要见解。本文旨在阐述其对乳腺癌管理的重要性。
基于当前文献，对参数化乳腺成像的现状及其在治疗管理中的重要性进行了综述。此外，还强调了未来的机遇和挑战。
乳腺癌的参数成像包括MRI、PET等核医学检查、不同技术的联合应用（PET-CT、PET-MRI）以及特定放射性示踪剂的使用。乳腺参数MRI主要使用T2加权成像、扩散加权成像（DWI）以及动态对比增强MRI（DCE-MRI）。定量和定性成像生物标志物为肿瘤生物学提供了见解，并有助于推断分子亚型或预后。
近年来，参数成像已在乳腺诊断中得到应用。它在不断发展，并且在未来几年将继续变得更加重要。它为改善乳腺癌的诊断和治疗管理提供了机会。
